> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tecentriq/Chemo Combo OK’d for Lung Cancer
- URL: https://www.fdaweb.com/tecentriq-chemo-combo-okd-for-lung-cancer/
- Published: 2019-12-04T12:00:00.000Z
- Updated: 2026-09-14T15:55:17.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145652

FDA has approved a Genentech supplemental BLA for Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane \[paclitaxel protein-bound; *nab*\-paclitaxel\] and carboplatin) for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations. Approval is based on data from the Phase 3 IMpower130 study, which the company says showed Tecentriq in combination with chemotherapy helped people live significantly longer compared to chemotherapy alone (median overall survival 18.6 months vs. 13.9 months). The combination also showed improved progression-free survival (7.2 months vs. 6.5 months), it says.

Genentech says that the combination’s safety profile appeared consistent with the known safety profiles of the individual medicines, and no new safety signals were identified. “Grade 3-4 treatment-related adverse events were reported in 73.2% of people receiving Tecentriq plus chemotherapy compared with 60.3% of people receiving chemotherapy alone,” it says.

Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1 to block its interactions with both PD-1 and B7-1 receptors, according to Genentech. “By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells,” it says.